All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On Sunday 2 December 2018, a Plenary Scientific Session took place at the 60th American Society of Hematology (ASH) Annual Meeting, San Diego, CA. During that session (Abstract #6), results from the phase III Alliance A041202 (NCT01886872) study were presented by Jennifer Woyach from the Ohio State University Comprehensive Cancer Center, Columbus, OH.
In this multicenter, randomized, NCI National Clinical Trials Network phase III trial bendamustine plus rituximab combination (BR; arm 1) was compared against ibrutinib alone (arm 2) or ibrutinib plus rituximab (IR; arm 3), in older untreated patients with chronic lymphocytic leukemia (CLL). This is one of the first studies to prospectively evaluate in this setting the potential benefit of rituximab addition to ibrutinib and the direct comparison of ibrutinib to BR. The primary endpoint of the study was progression-free survival (PFS), while overall survival (OS) was a secondary endpoint. The results of this trial have also been recently published in the New England Journal of Medicine.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox